XtalPi Unveils Kodexia™: World's First Closed-Loop siRNA Platform, Slashing Drug Discovery Timelines

XtalPi Holdings Limited (HKEX: 2228), an AI and robotics-driven drug discovery company, today unveiled Kodexia™, the industry's first closed-loop small interfering RNA (siRNA) discovery platform that combines generative AI, first-principles-driven biological modeling, and automated experimentation. The announcement, made from Boston and Beijing on October 6, 2026, marks a significant leap in nucleic acid therapeutics, with XtalPi simultaneously advancing six proprietary preclinical programs targeting metabolic, renal, respiratory, and central nervous system diseases.

Kodexia™ addresses longstanding bottlenecks in siRNA development, including fragmented design processes, patent barriers, and poor translation from cellular assays to animal models. At its core is siFormer, a proprietary architecture that integrates RNA thermodynamics and structural features to guide molecular generation toward biologically plausible designs. The platform operates through a closed-loop system where generative models continuously interact with XtalPi's automated laboratories, which conduct over 500 in vitro and 30 in vivo experiments weekly. This integration has yielded a nearly threefold increase in design efficiency, with more than 50% of first-round designs showing stronger in vivo activity than positive controls. The lead program in IgA nephropathy reached non-human primate efficacy data within seven months, demonstrating greater activity and durability than a clinical-stage reference molecule, and is on track for preclinical candidate selection within nine months—significantly faster than the industry norm of 12 to 18 months.

The debut of Kodexia™ positions XtalPi at the forefront of RNA interference therapies, potentially accelerating the delivery of next-generation RNA therapies for patients worldwide. By co-optimizing siRNA molecules with targeting systems for extrahepatic delivery to the kidney, spleen, and adipose tissue, the platform expands the therapeutic reach of siRNA beyond the liver. As XtalPi continues to advance its internal assets and collaborations, the industry will be watching closely to see how this integrated computational-experimental workflow transforms drug development and whether it can consistently deliver on its promise of faster, more efficient discovery.